No effect of oral hormone replacement therapy on platelet function in postmenopausal women with coronary artery disease

N. Håkan Wallén; Nailin Li; Margita Eriksson-Berg; Britt-Marie Landgren; Karin Schenck-Gustafsson; Paul Hjemdahl

doi:10.1160/TH06-09-0531

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(06): 862-863
DOI: 10.1160/TH06-09-0531

Letters to the Editor

Schattauer GmbH

No effect of oral hormone replacement therapy on platelet function in postmenopausal women with coronary artery disease

N. Håkan Wallén

¹Department of Medicine, Clinical Pharmacology, Solna, Karolinska Institutet, Sweden

³Department of Clinical Sciences, Division of Internal Medicine, Danderyds Hospital, Stockholm, Sweden

,

Nailin Li

¹Department of Medicine, Clinical Pharmacology, Solna, Karolinska Institutet, Sweden

,

Margita Eriksson-Berg

²Cardiology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Sweden

,

Britt-Marie Landgren

⁴Department of Obstetrics and Gynecology, Karolinska University Hospital, Huddinge, Sweden

,

Karin Schenck-Gustafsson

²Cardiology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Sweden

,

Paul Hjemdahl

¹Department of Medicine, Clinical Pharmacology, Solna, Karolinska Institutet, Sweden

› Author Affiliations

Abstract

Full Text

References

References
1 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605-13.
2 Wassertheil-Smoller S, Hendrix SL, Limacher M. et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. J Am Med Assoc 2003; 289: 2673-84.
3 Manson JE, Hsia J, Johnson KC. et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
4 Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women’s Health Initiative. Arterioscler Thromb Vasc Biol 2003; 23: 11-6.
5 Li N, Soop A, Sollevi A. et al. Multi-cellular activation in vivo by endotoxin in humans--limited protection by adenosine infusion. Thromb Haemost 2000; 84: 381-7.
6 Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154-61.
7 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.
8 Teede HJ, McGrath BP, Turner A. et al. Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women. Clin Sci (Lond) 2001; 100: 207-13.
9 Nakano Y, Oshima T, Ozono R. et al. Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate. Cardiovasc Res 2002; 53: 634-41.
10 Thijs A, van Baal WM, van der Mooren MJ. et al. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest 2002; 32: 613-8.
11 Rinder CS, Student LA, Bonan JL. et al. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993; 82: 505-12.
12 Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-70.